Molecular Partners Ag (MOLN) Capital Expenditures (2020 - 2025)
Molecular Partners Ag (MOLN) posted quarterly Capital Expenditures of $894054.7 for Q4 2025, up 11.0% year-over-year from $805422.4 in Q4 2024, and up 31.61% quarter-over-quarter from $679340.8 in Q3 2025.
Molecular Partners Ag (MOLN) Capital Expenditures (2020 - 2025) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Capital Expenditures for 6 consecutive years, with $894054.7 the latest figure, recorded in Q4 2025.
- In Q4 2025, Capital Expenditures rose 11.0% year-over-year to $894054.7; the TTM figure through Dec 2025 stood at $916346.0 (up 11.77% YoY), while the FY2025 annual figure was $893335.2, up 11.0% from the prior year.
- Capital Expenditures rose to $894054.7 in Q4 2025 per MOLN's latest filing, from $679340.8 in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.2 million in Q4 2022 and bottomed at -$656551.1 in Q2 2025.
- Historically, Capital Expenditures has averaged $230908.0 across 5 years, with a median of $104755.7 in 2023.
- Annual changes were most pronounced in 2022 — Capital Expenditures surged 274.38% — and 2025, when it slumped 256.5%.
- Molecular Partners Ag's Capital Expenditures stood at $1.0 million in 2021, then gained by 20.72% to $1.2 million in 2022, then tumbled by 46.94% to $648541.1 in 2023, then increased by 24.19% to $805422.4 in 2024, then climbed by 11.0% to $894054.7 in 2025.
- Business Quant data shows MOLN's Capital Expenditures at $894054.7 in Q4 2025, $679340.8 in Q3 2025, and -$656551.1 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 251.02 Mn |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 894,054.65 |
| Dec 31, 2025 | 894,054.65 |
| Sep 30, 2025 | 679,340.76 |
| Sep 30, 2025 | 679,340.76 |
| Jun 30, 2025 | -656,551.15 |
| Jun 30, 2025 | -656,551.15 |
| Mar 31, 2025 | -498.29 |
| Mar 31, 2025 | -498.29 |
| Dec 31, 2024 | 805,422.43 |
| Dec 31, 2024 | 805,422.43 |
| Sep 30, 2024 | 359,455.92 |
| Sep 30, 2024 | 359,455.92 |
| Jun 30, 2024 | -344,872.66 |
| Jun 30, 2024 | -344,872.66 |
| Mar 31, 2024 | -139.77 |
| Mar 31, 2024 | -139.77 |
| Dec 31, 2023 | 648,541.10 |
| Dec 31, 2023 | 648,541.10 |
| Sep 30, 2023 | 209,134.62 |
| Sep 30, 2023 | 209,134.62 |